Global Information
회사소개 | 문의 | 비교리스트

세계의 당뇨병 치료제 시장(2020-2026년)

Antidiabetics Market Size By Product, By Patient Population, By Route of Administration, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

리서치사 Global Market Insights Inc.
발행일 2020년 06월 상품 코드 945465
페이지 정보 영문 202 Pages
가격
US $ 5,150 ₩ 6,052,000 Unprintable PDF (Single User License)
US $ 7,150 ₩ 8,402,000 Printable PDF (Multi User License)
US $ 9,150 ₩ 10,753,000 Printable PDF (Enterprise User License)


세계의 당뇨병 치료제 시장(2020-2026년) Antidiabetics Market Size By Product, By Patient Population, By Route of Administration, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026
발행일 : 2020년 06월 페이지 정보 : 영문 202 Pages

당뇨병 치료제 시장은 당뇨병 유병률 상승, 의약품 개발 증가, 경구 당뇨병 치료제의 높은 도입률 등의 요인으로 향후 수년간 지수함수적으로 성장할 것으로 예측됩니다. 제품 부문별로 보면 DPP-IV 부문이 2019년에 80억 달러 이상의 매출을 나타냈습니다. DPP-IV는 체중 증가를 일으키지 않고 공복시와 식후 혈당치를 저하시켜 2형 당뇨병 환자에게 널리 사용되고 있습니다. 투약 경로별로는 인슐린 주사기/인슐린 펜 부문이 15.5% 이상의 매출 점유율을 차지하고 있으며, 예측기간 중 대폭적인 성장이 전망됩니다. 인슐린 펜의 편리한 사용과 인슐린 주사의 유연성으로 당뇨병 관리가 개선되고 당뇨병 환자의 삶의 질이 유지됩니다.

세계의 당뇨병 치료제 시장을 조사했으며, 시장 및 제품 개요, 시장 성장에 대한 각종 영향요인 분석, 산업 생태계, 규제 상황, 시장 규모 추정과 예측, 제품·환자 구분·투여 경로·지역/주요 국가 등 각종 세분화별 내역, 경쟁 상황, 시장 점유율, 주요 기업 개요 등을 정리했습니다.

제1장 조사 방법

제2장 주요 요약

제3장 산업 분석

  • 산업 세분화
  • 산업 추정과 예측
  • 산업에 대한 영향요인
  • 규제 상황 : 지역별
  • 임상 워크플로우 분석
  • 상환 시나리오 : 지역별
  • 성장 잠재성
  • COVID-19의 영향 분석
  • Porter's Five Forces 분석
  • 경쟁 상황
  • PESTEL 분석

제4장 시장 분석과 예측 : 제품별

  • 주요 동향
  • 인슐린
    • 초속효형 아날로그
    • 지효형 아날로그
    • 프리믹스 인슐린
    • 단시간 작용형 아날로그
    • 중등도 작용형 아날로그
  • 약제 클래스
    • 알파 글루코시다아제 억제제
    • 바이구아니드
    • 설포닐우레아
    • GLP-1 유사체
    • DPP-IV 억제제
    • 메글리티나이드
    • SGLT-II 억제제
    • 치아졸리딘디온

제5장 시장 분석과 예측 : 환자 구분별

  • 주요 동향
  • 소아
  • 성인
  • 고령자

제6장 시장 분석과 예측 : 투여 경로별

  • 주요 동향
  • 인슐린 주사기/인슐린 펜
  • 인슐린 펌프
  • 정맥내 주입
  • 경구
  • 기타

제7장 시장 분석과 예측 : 지역별

  • 지역 동향
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
  • 라틴아메리카
    • 브라질
    • 멕시코
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아

제8장 기업 개요

  • 경쟁 대시보드
  • AstraZeneca
  • Bayer Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Halozyme Therapeutics
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk
  • Oramed Pharmaceuticals Inc.
  • Pfizer
  • Sanofi
  • Takeda Pharmaceutical
KSM 20.07.14

Data Tables

  • TABLE 1. Antidiabetics industry 360 degree synopsis, 2015 - 2019
  • TABLE 2. Global antidiabetics market, 2015 - 2019 (USD Million)
  • TABLE 3. Global antidiabetics market, 2020 - 2026 (USD Million)
  • TABLE 4. Global antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 5. Global antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 6. Global antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 7. Global antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 8. Global antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 9. Global antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 10. Global antidiabetics market, by region, 2015 - 2019 (USD Million)
  • TABLE 11. Global antidiabetics market, by region, 2020 - 2026 (USD Million)
  • TABLE 12. Industry impact forces
  • TABLE 13. Rapid acting analog market size, by region, 2015 - 2019 (USD Million)
  • TABLE 14. Rapid acting analog market size, by region, 2020 - 2026 (USD Million)
  • TABLE 15. Long acting analog market size, by region, 2015 - 2019 (USD Million)
  • TABLE 16. Long acting analog market size, by region, 2020 - 2026 (USD Million)
  • TABLE 17. Premixed insulin market size, by region, 2015 - 2019 (USD Million)
  • TABLE 18. Premixed insulin market size, by region, 2020 - 2026 (USD Million)
  • TABLE 19. Short acting analog market size, by region, 2015 - 2019 (USD Million)
  • TABLE 20. Short acting analog market size, by region, 2020 - 2026 (USD Million)
  • TABLE 21. Intermediate acting insulin market size, by region, 2015 - 2019 (USD Million)
  • TABLE 22. Intermediate acting insulin market size, by region, 2020 - 2026 (USD Million)
  • TABLE 23. Drug class market size, by region, 2015 - 2019 (USD Million)
  • TABLE 24. Drug class market size, by region, 2020 - 2026 (USD Million)
  • TABLE 25. Alpha glucosidase inhibitors market size, by region, 2015 - 2019 (USD Million)
  • TABLE 26. Alpha glucosidase inhibitors market size, by region, 2020 - 2026 (USD Million)
  • TABLE 27. Biguanides market size, by region, 2015 - 2019 (USD Million)
  • TABLE 28. Biguanides market size, by region, 2020 - 2026 (USD Million)
  • TABLE 29. Sulphonylureas market size, by region, 2015 - 2019 (USD Million)
  • TABLE 30. Sulphonylureas market size, by region, 2020 - 2026 (USD Million)
  • TABLE 31. GLP-1 (Glucagon like peptide) agonists market size, by region, 2015 - 2019 (USD Million)
  • TABLE 32. GLP-1 (Glucagon like peptide) agonists market size, by region, 2020 - 2026 (USD Million)
  • TABLE 33. DPP-IV (Dipeptidyl Peptidase) inhibitors market size, by region, 2015 - 2019 (USD Million)
  • TABLE 34. DPP-IV (Dipeptidyl Peptidase) inhibitors market size, by region, 2020 - 2026 (USD Million)
  • TABLE 35. Meglitinides market size, by region, 2015 - 2019 (USD Million)
  • TABLE 36. Meglitinides market size, by region, 2020 - 2026 (USD Million)
  • TABLE 37. SGLT-II (Sodium Glucose Transport Proteins) inhibitors market size, by region, 2015 - 2019 (USD Million)
  • TABLE 38. SGLT-II (Sodium Glucose Transport Proteins) inhibitors market size, by region, 2020 - 2026 (USD Million)
  • TABLE 39. Thiazolidinedione market size, by region, 2015 - 2019 (USD Million)
  • TABLE 40. Thiazolidinedione market size, by region, 2020 - 2026 (USD Million)
  • TABLE 41. Pediatric market size, by region, 2015 - 2019 (USD Million)
  • TABLE 42. Pediatric market size, by region, 2020 - 2026 (USD Million)
  • TABLE 43. Adult market size, by region, 2015 - 2019 (USD Million)
  • TABLE 44. Adult market size, by region, 2020 - 2026 (USD Million)
  • TABLE 45. Geriatric market size, by region, 2015 - 2019 (USD Million)
  • TABLE 46. Geriatric market size, by region, 2020 - 2026 (USD Million)
  • TABLE 47. Insulin syringe/ Insulin pen market size, by region, 2015 - 2019 (USD Million)
  • TABLE 48. Insulin syringe/ Insulin pen market size, by region, 2020 - 2026 (USD Million)
  • TABLE 49. Insulin pump market size, by region, 2015 - 2019 (USD Million)
  • TABLE 50. Insulin pump market size, by region, 2020 - 2026 (USD Million)
  • TABLE 51. Intravenous infusion market size, by region, 2015 - 2019 (USD Million)
  • TABLE 52. Intravenous infusion market size, by region, 2020 - 2026 (USD Million)
  • TABLE 53. Oral market size, by region, 2015 - 2019 (USD Million)
  • TABLE 54. Oral market size, by region, 2020 - 2026 (USD Million)
  • TABLE 55. Others market size, by region, 2015 - 2019 (USD Million)
  • TABLE 56. Others market size, by region, 2020 - 2026 (USD Million)
  • TABLE 57. North America market, by country, 2015 - 2019 (USD Million)
  • TABLE 58. North America market, by country, 2020 - 2026 (USD Million)
  • TABLE 59. North America antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 60. North America antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 61. North America antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 62. North America antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 63. North America antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 64. North America antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 65. North America antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 66. North America antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 67. North America antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 68. North America antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 69. U.S. antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 70. U.S. antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 71. U.S. antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 72. U.S. antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 73. U.S. antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 74. U.S. antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 75. U.S. antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 76. U.S. antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 77. U.S. antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 78. U.S. antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 79. Canada antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 80. Canada antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 81. Canada antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 82. Canada antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 83. Canada antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 84. Canada antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 85. Canada antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 86. Canada antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 87. Canada antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 88. Canada antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 89. Europe market, by country, 2015 - 2019 (USD Million)
  • TABLE 90. Europe market, by country, 2020 - 2026 (USD Million)
  • TABLE 91. Europe antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 92. Europe antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 93. Europe antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 94. Europe antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 95. Europe antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 96. Europe antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 97. Europe antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 98. Europe antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 99. Europe antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 100. Europe antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 101. Germany antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 102. Germany antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 103. Germany antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 104. Germany antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 105. Germany antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 106. Germany antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 107. Germany antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 108. Germany antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 109. Germany antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 110. Germany antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 111. UK antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 112. UK antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 113. UK antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 114. UK antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 115. UK antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 116. UK antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 117. UK antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 118. UK antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 119. UK antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 120. UK antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 121. France antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 122. France antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 123. France antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 124. France antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 125. France antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 126. France antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 127. France antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 128. France antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 129. France antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 130. France antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 131. Italy antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 132. Italy antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 133. Italy antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 134. Italy antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 135. Italy antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 136. Italy antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 137. Italy antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 138. Italy antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 139. Italy antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 140. Italy antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 141. Spain antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 142. Spain antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 143. Spain antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 144. Spain antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 145. Spain antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 146. Spain antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 147. Spain antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 148. Spain antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 149. Spain antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 150. Spain antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 151. Asia Pacific market size, by country, 2015 - 2019 (USD Million)
  • TABLE 152. Asia Pacific market size, by country, 2020 - 2026 (USD Million)
  • TABLE 153. Asia Pacific antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 154. Asia Pacific antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 155. Asia Pacific antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 156. Asia Pacific antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 157. Asia Pacific antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 158. Asia Pacific antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 159. Asia Pacific antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 160. Asia Pacific antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 161. Asia Pacific antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 162. Asia Pacific antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 163. Japan antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 164. Japan antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 165. Japan antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 166. Japan antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 167. Japan antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 168. Japan antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 169. Japan antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 170. Japan antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 171. Japan antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 172. Japan antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 173. China antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 174. China antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 175. China antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 176. China antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 177. China antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 178. China antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 179. China antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 180. China antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 181. China antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 182. China antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 183. India antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 184. India antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 185. India antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 186. India antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 187. India antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 188. India antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 189. India antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 190. India antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 191. India antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 192. India antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 193. Australia antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 194. Australia antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 195. Australia antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 196. Australia antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 197. Australia antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 198. Australia antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 199. Australia antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 200. Australia antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 201. Australia antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 202. Australia antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 203. Latin America market size, by country, 2015 - 2019 (USD Million)
  • TABLE 204. Latin America market size, by country, 2020 - 2026 (USD Million)
  • TABLE 205. Latin America antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 206. Latin America antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 207. Latin America antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 208. Latin America antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 209. Latin America antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 210. Latin America antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 211. Latin America antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 212. Latin America antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 213. Latin America antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 214. Latin America antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 215. Brazil antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 216. Brazil antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 217. Brazil antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 218. Brazil antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 219. Brazil antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 220. Brazil antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 221. Brazil antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 222. Brazil antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 223. Brazil antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 224. Brazil antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 225. Mexico antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 226. Mexico antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 227. Mexico antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 228. Mexico antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 229. Mexico antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 230. Mexico antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 231. Mexico antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 232. Mexico antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 233. Mexico antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 234. Mexico antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 235. MEA market size, by country, 2015 - 2019 (USD Million)
  • TABLE 236. MEA market size, by country, 2020 - 2026 (USD Million)
  • TABLE 237. MEA antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 238. MEA antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 239. MEA antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 240. MEA antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 241. MEA antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 242. MEA antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 243. MEA antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 244. MEA antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 245. MEA antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 246. MEA antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 247. South Africa antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 248. South Africa antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 249. South Africa antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 250. South Africa antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 251. South Africa antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 252. South Africa antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 253. South Africa antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 254. South Africa antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 255. South Africa antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 256. South Africa antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 257. Saudi Arabia antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 258. Saudi Arabia antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 259. Saudi Arabia antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 260. Saudi Arabia antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 261. Saudi Arabia antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 262. Saudi Arabia antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 263. Saudi Arabia antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 264. Saudi Arabia antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 265. Saudi Arabia antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 266. Saudi Arabia antidiabetics market, by route of administration, 2020 - 2026 (USD Million)

Charts & Figures

  • FIG.1. U.S. states with highest incidence of type 2 diabetes in the year 2016
  • FIG.2. Antidiabetics market, 2015 - 2026 (USD Million)
  • FIG.3. Clinical workflow analysis for cost optimization in middle- and low-income countries
  • FIG.4. Growth potential analysis, by product
  • FIG.5. Growth potential analysis, by patient population
  • FIG.6. Growth potential analysis, by route of administration
  • FIG.7. Porter's analysis
  • FIG.8. PESTEL analysis
  • FIG.9. Company share analysis, 2019
  • FIG.10. Competitive dashboard, 2019

Title:
Antidiabetics Market Size By Product (Insulin {Rapid Acting, Long Acting, Premixed Insulin, Short Acting, Intermediate Acting}, Drug Class {Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 Agonist, Meglitinides, DPP-4 Inhibitors, SGLT-2, Thiazolidinedione}), By Patient Population (Pediatric, Adult, Geriatric), By Route of Administration (Insulin Syringe/Insulin Pen, Insulin Pump, Intravenous Infusion, Oral), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026 .

The antidiabetic market is projected to expand exponentially over the coming years owing to the rising prevalence of diabetes, increasing drug development, and high retail adoption of oral antidiabetics. Antidiabetic drugs are basically medicines which are specifically developed to stabilize and control blood glucose levels among people who are diagnosed with diabetes.

Antidiabetic drugs are generally used to manage the conditions associated diabetes. These drugs essentially help patients with their diabetes by keeping their condition under control. this effectively lowers their risk of developing any diabetes-related complications.

Diabetes patients might have to consume antidiabetic drugs for their entire lives so as to control their blood glucose levels and also to prevent hyperglycemia and hypoglycemia. This creates an immense demand for these drugs in the pharmaceutical industry, ensuring market growth.

The anti-diabetic market is segmented in terms of product, patient population, route of administration, and regional landscape.

Based on product, the antidiabetic market is classified into insulin, and drug class. The drug class segment is further classified into thiazolidinedione, SGLT-II, meglitinides, DPP-IV, GLP-I, sulphonylureas, biguanides, and alpha glucosidase inhibitors. Among these, DPP-IV segment represented over $8.0 billion revenue in 2019. DPP-IV reduces both fasting and postprandial (after food) blood glucose levels, without causing any weight gain, and is widely used for type-2 diabetic patients.

DPP-IV usually come in pill form and are consumed orally. These are either used alone or can be used in combination with other medicines related to diabetes.

With respect to patient population, the antidiabetic market is categorized into geriatric, adult, and pediatric. Pediatric segment is likely to witness growth owing to the increasing incidence of diabetes among children owing to a high consumption of carbohydrate-rich diet. This segment is projected to witness a CAGR of over 11.5% through the analysis period.

In terms of route of administration, the overall antidiabetic market is bifurcated into oral, intravenous infusion, insulin pump, insulin syringe/ insulin pen, and others. The insulin syringe/insulin pen segment represents a revenue share of more than 15.5% and is likely to witness appreciative growth over the projected time period. Ease of use of insulin pens and the flexibility of incorporating insulin injections improves diabetes control and maintains quality of life for the diabetic patients.

Additionally, a person should replace the disposable needle after using the injection of insulin, which fuels product adoption in a considerable manner. Additionally, with proper care taken, the insulin pens tend to last for many years.

From a regional frame of reference, Europe antidiabetic market is projected to witness a CAGR of over 10.7% through the analysis period. High retail adoption of oral antidiabetics, increasing drug development and consumption of novel drugs will thus lead to growth of this region.

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
  • 1.2. Market definitions
  • 1.3. Forecast parameters
  • 1.4. Data sources
    • 1.4.1. Secondary
      • 1.4.1.1. Paid sources
      • 1.4.1.2. Unpaid sources
    • 1.4.2. Primary

Chapter 2. Executive Summary

  • 2.1. Antidiabetics industry 360 degree synopsis, 2015 - 2026
    • 2.1.1. Business trends
    • 2.1.2. Product trends
    • 2.1.3. Patient population trends
    • 2.1.4. Route of administration trends
    • 2.1.5. Regional trends

Chapter 3. Antidiabetics Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2015 - 2026
  • 3.3. Industry impact forces
    • 3.3.1. Growth drivers
      • 3.3.1.1. Strong product pipeline of antidiabetics
      • 3.3.1.2. Globally rising prevalence of diabetes
      • 3.3.1.3. Increasing prevalence of lifestyle induced disorders such as obesity
      • 3.3.1.4. Growing adoption of oral antidiabetic drugs
      • 3.3.1.5. Rising spending on R&D for innovative drugs
    • 3.3.2. Industry pitfalls and challenges
      • 3.3.2.1. Prohibitive cost of insulin
      • 3.3.2.2. Safety issues pertaining to some diabetic drugs
  • 3.4. Regulatory landscape
    • 3.4.1. U.S.
    • 3.4.2. Europe
  • 3.5. Clinical workflow analysis
  • 3.6. Reimbursement scenario
    • 3.6.1. U.S.
    • 3.6.2. Europe
    • 3.6.3. Australia
  • 3.7. Growth potential analysis
    • 3.7.1. By product
    • 3.7.2. By patient population
    • 3.7.3. By route of administration
  • 3.8. COVID-19 impact analysis
  • 3.9. Porter's analysis
  • 3.10. Competitive landscape, 2019
  • 3.11. PESTEL analysis

Chapter 4. Antidiabetics Market, By Product

  • 4.1. Key segment trends
  • 4.2. Insulin
    • 4.2.1. Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.2. Rapid acting analog
      • 4.2.2.1. Market size, by region, 2015-2026 (USD Million)
    • 4.2.3. Long acting analog
      • 4.2.3.1. Market size, by region, 2015-2026 (USD Million)
    • 4.2.4. Premixed insulin
      • 4.2.4.1. Market size, by region, 2015-2026 (USD Million)
    • 4.2.5. Short acting analog
      • 4.2.5.1. Market size, by region, 2015-2026 (USD Million)
    • 4.2.6. Intermediate acting analog
      • 4.2.6.1. Market size, by region, 2015-2026 (USD Million)
  • 4.3. Drug class
    • 4.3.1. Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.2. Alpha glucosidase inhibitors
      • 4.3.2.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.3. Biguanides
      • 4.3.3.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.4. Sulphonylureas
      • 4.3.4.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.5. GLP-1 (Glucagon like peptide) agonists
      • 4.3.5.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.6. DPP-IV (Dipeptidyl Peptidase) inhibitors
      • 4.3.6.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.7. Meglitinides
      • 4.3.7.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.8. SGLT-II (Sodium Glucose Transport Proteins) inhibitors
      • 4.3.8.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.9. Thiazolidinedione
      • 4.3.9.1. Market size, by region, 2015-2026 (USD Million)

Chapter 5. Antidiabetics Market, By Patient Population

  • 5.1. Key segment trends
  • 5.2. Pediatric
    • 5.2.1. Market size, by region, 2015 - 2026 (USD Million)
  • 5.3. Adult
    • 5.3.1. Market size, by region, 2015 - 2026 (USD Million)
  • 5.4. Geriatric
    • 5.4.1. Market size, by region, 2015 - 2026 (USD Million)

Chapter 6. Antidiabetics Market, By Route of Administration

  • 6.1. Key segment trends
  • 6.2. Insulin syringe/ Insulin pen
    • 6.2.1. Market size, by region, 2015 - 2026 (USD Million)
  • 6.3. Insulin pump
    • 6.3.1. Market size, by region, 2015 - 2026 (USD Million)
  • 6.4. Intravenous infusion
    • 6.4.1. Market size, by region, 2015 - 2026 (USD Million)
  • 6.5. Oral
    • 6.5.1. Market size, by region, 2015 - 2026 (USD Million)
  • 6.6. Others
    • 6.6.1. Market size, by region, 2015 - 2026 (USD Million)

Chapter 7. Antidiabetics Market, By Region

  • 7.1. Key regional trends
  • 7.2. North America
    • 7.2.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.2.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.2.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.2.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.2.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.2.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.2.5. U.S.
      • 7.2.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.2.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.2.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.2.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.2.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.2.6. Canada
      • 7.2.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.2.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.2.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.2.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.2.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
  • 7.3. Europe
    • 7.3.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.3.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.3.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.3.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.3.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.3.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.5. Germany
      • 7.3.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.6. UK
      • 7.3.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.7. France
      • 7.3.7.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.7.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.7.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.7.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.7.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.8. Italy
      • 7.3.8.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.8.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.8.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.8.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.8.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.9. Spain
      • 7.3.9.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.9.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.9.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.9.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.9.3. Market size by route of administration, 2015 - 2026 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.4.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.4.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.4.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.4.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.4.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.4.5. Japan
      • 7.4.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.4.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.4.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.4.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.4.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.4.6. China
      • 7.4.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.4.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.4.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.4.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.4.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.4.7. India
      • 7.4.7.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.4.7.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.4.7.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.4.7.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.4.7.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.4.8. Australia
      • 7.4.8.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.4.8.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.4.8.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.4.8.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.4.8.3. Market size by route of administration, 2015 - 2026 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.5.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.5.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.5.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.5.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.5.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.5.5. Brazil
      • 7.5.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.5.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.5.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.5.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.5.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.5.6. Mexico
      • 7.5.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.5.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.5.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.5.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.5.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
  • 7.6. Middle East & Africa (MEA)
    • 7.6.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.6.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.6.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.6.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.6.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.6.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.6.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.6.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.6.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.6.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.6.6. Saudi Arabia
      • 7.6.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.6.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.6.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.6.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.6.6.3. Market size by route of administration, 2015 - 2026 (USD Million)

Chapter 8. Company Profiles

  • 8.1. Competitive dashboard, 2019
  • 8.2. AstraZeneca
    • 8.2.1. Business overview
    • 8.2.2. Financial data
    • 8.2.3. Product landscape
    • 8.2.4. Strategic outlook
    • 8.2.5. SWOT analysis
  • 8.3. Bayer Corporation
    • 8.3.1. Business overview
    • 8.3.2. Financial data
    • 8.3.3. Product landscape
    • 8.3.4. Strategic outlook
    • 8.3.5. SWOT analysis
  • 8.4. Boehringer Ingelheim
    • 8.4.1. Business overview
    • 8.4.2. Financial data
    • 8.4.3. Product landscape
    • 8.4.4. Strategic outlook
    • 8.4.5. SWOT analysis
  • 8.5. Bristol-Myers Squibb
    • 8.5.1. Business overview
    • 8.5.2. Financial data
    • 8.5.3. Product landscape
    • 8.5.4. Strategic outlook
    • 8.5.5. SWOT analysis
  • 8.6. Eli Lilly
    • 8.6.1. Business overview
    • 8.6.2. Financial data
    • 8.6.3. Product landscape
    • 8.6.4. Strategic outlook
    • 8.6.5. SWOT analysis
  • 8.7. Halozyme Therapeutics
    • 8.7.1. Business overview
    • 8.7.2. Financial data
    • 8.7.3. Product landscape
    • 8.7.4. Strategic outlook
    • 8.7.5. SWOT analysis
  • 8.8. Johnson & Johnson
    • 8.8.1. Business overview
    • 8.8.2. Financial data
    • 8.8.3. Product landscape
    • 8.8.4. Strategic outlook
    • 8.8.5. SWOT analysis
  • 8.9. Merck & Co. Inc.
    • 8.9.1. Business overview
    • 8.9.2. Financial data
    • 8.9.3. Product landscape
    • 8.9.4. Strategic outlook
    • 8.9.5. SWOT analysis
  • 8.10. Novartis AG
    • 8.10.1. Business overview
    • 8.10.2. Financial data
    • 8.10.3. Product landscape
    • 8.10.4. Strategic outlook
    • 8.10.5. SWOT analysis
  • 8.11. Novo Nordisk
    • 8.11.1. Business overview
    • 8.11.2. Financial data
    • 8.11.3. Product landscape
    • 8.11.4. Strategic outlook
    • 8.11.5. SWOT analysis
  • 8.12. Oramed Pharmaceuticals Inc.
    • 8.12.1. Business overview
    • 8.12.2. Financial data
    • 8.12.3. Product landscape
    • 8.12.4. Strategic outlook
    • 8.12.5. SWOT analysis
  • 8.13. Pfizer
    • 8.13.1. Business overview
    • 8.13.2. Financial data
    • 8.13.3. Product landscape
    • 8.13.4. Strategic outlook
    • 8.13.5. SWOT analysis
  • 8.14. Sanofi
    • 8.14.1. Business overview
    • 8.14.2. Financial data
    • 8.14.3. Product landscape
    • 8.14.4. Strategic outlook
    • 8.14.5. SWOT analysis
  • 8.15. Takeda Pharmaceutical
    • 8.15.1. Business overview
    • 8.15.2. Financial data
    • 8.15.3. Product landscape
    • 8.15.4. Strategic outlook
    • 8.15.5. SWOT analysis
Back to Top
전화 문의
F A Q